Customer M&A could disrupt supply agreements
A major customer (Denver/Archimemet) is being acquired; management acknowledged change of ownership could pose risks but expects continuity.
medium · analyst_question
Neuland Laboratories Limited — Q4 FY26
Neuland Laboratories delivered a record Q4 FY26 with revenue of ₹788.7 crore (up 134.9% YoY), driven by commercial CDMO shipments and favorable exchange rates.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Geopolitical supply chain volatility
Management flagged higher freight costs due to Middle East conflict and is monitoring raw material price volatility.
medium · management_commentaryLumpy quarterly performance may persist
Management cautioned that volatility from high-value new molecules will continue, making quarterly predictions unreliable.
low · management_commentaryTranscript manipulation allegation
An investor alleged that a previous call transcript was altered; management promised to check but did not provide immediate clarity.
low · analyst_question